TRANEXAMIC ACID INJECTION SOLUTION

Maa: Kanada

Kieli: englanti

Lähde: Health Canada

Aktiivinen ainesosa:

TRANEXAMIC ACID

Saatavilla:

AURO PHARMA INC

ATC-koodi:

B02AA02

INN (Kansainvälinen yleisnimi):

TRANEXAMIC ACID

Annos:

100MG

Lääkemuoto:

SOLUTION

Koostumus:

TRANEXAMIC ACID 100MG

Antoreitti:

INTRAVENOUS

Kpl paketissa:

100

Prescription tyyppi:

Prescription

Terapeuttinen alue:

HEMOSTATICS

Tuoteyhteenveto:

Active ingredient group (AIG) number: 0114760002; AHFS:

Valtuutuksen tilan:

APPROVED

Valtuutus päivämäärä:

2019-01-18

Valmisteyhteenveto

Page 1 of 26
_PRODUCT MONOGRAPH _
_TRANEXAMIC ACID INJECTION _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TRANEXAMIC ACID INJECTION
Tranexamic acid injection
Solution, 100 mg / mL, Intravenous
House Standard
Antifibrinolytic agent
AURO PHARMA INC.
Date of Revision:
3700 Steeles Avenue West, Suite # 402
January 15, 2019
Woodbridge, Ontario, L4L 8K8,
Canada.
Date of Initial Authorization:
July 06, 2017
Date of Revision:
January 03, 2023
Submission Control Number: 266686
Page 2 of 26
_PRODUCT MONOGRAPH _
_TRANEXAMIC ACID INJECTION _
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
01/2023
4 DOSAGE AND ADMINISTRATION, 4.4 Administration
01/2023
7 WARNINGS AND PRECAUTIONS
01/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
3
1 INDICATIONS
......................................................................................................................
4
1.1 Pediatrics
..............................................................................................................
4
1.2 Geriatrics
..............................................................................................................
4
2 CONTRAINDICATIONS
.........................................................................................................
4
4 DOSAGE AND
ADMINISTRATION.........................................................................................
4
4.1 Dosing Considerations
...........................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
........................................................ 5
4.3 Reconstitution
......................................................................................................
5
4.4 Administration